RXRX Earnings & Financial Statements
Recursion Pharmaceuticals, Inc.
$3.86
+$0.12(+3.21%)
59
Overall
60
Value
75
Tech
44
Quality
Market Cap
$2.00B
Volume
14.79M
52W Range
$2.77 - $7.18
Target Price
$6.90
RXRX earnings and financial statements: Recursion Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
RXRX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $74.68M | $58.84M | $44.58M | $39.68M | $10.18M |
| Cost of revenue | $70.95M | $45.24M | $42.59M | $48.27M | - |
| Operating income | -$648.13M | -$479.00M | -$350.06M | -$245.73M | -$182.78M |
| EBITDA | -$561.19M | -$428.29M | -$307.73M | -$288.89M | -$175.12M |
| Net income | -$644.76M | -$463.66M | -$328.07M | -$239.48M | -$186.48M |
| EPS (diluted) | $-1.44 | $-1.69 | $-1.58 | $-1.36 | $-1.49 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $1.47B | $1.45B | $653.70M | $701.29M | $610.35M |
| Total liabilities | $343.26M | $413.82M | $190.26M | $215.48M | $67.41M |
| Shareholders’ equity | $1.13B | $1.03B | $463.44M | $485.81M | $542.94M |
| Cash and equivalents | $743.29M | $594.35M | $391.56M | $549.91M | $285.12M |
| Long-term debt | $56.21M | $86.27M | $44.52M | $44.96M | $633.0K |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$371.81M | -$359.17M | -$287.78M | -$83.52M | -$158.61M |
| Capital expenditure | -$8.63M | -$17.05M | -$12.55M | -$37.36M | -$39.80M |
| Free cash flow | -$380.44M | -$376.22M | -$300.33M | -$120.88M | -$198.41M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RXRX | $3.86 | +3.2% | 14.79M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Recursion Pharmaceuticals, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW